Aplastic Anemia in HIV: Updates in Transfusion Medicine Practices

Article · September 2024

CITATIONS
0

READS
6

1 author:

Emmanuel Ifeanyi Obeagu
Africa University
2,100 PUBLICATIONS **36,090** CITATIONS

SEE PROFILE

Elite Journal of Haematology. Volume 2 Issue 9(2024), Pp. 46-57

https://epjournals.com/journals/EJH

Aplastic Anemia in HIV: Updates in Transfusion Medicine Practices

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) in HIV-infected patients presents a complex clinical challenge due to the interplay between bone marrow failure and compromised immune status. Recent advancements in transfusion medicine have significantly impacted the management of AA in this vulnerable population. This review explores the latest updates in transfusion practices, focusing on improved blood screening technologies, transfusion protocols, and infection control measures. Enhanced nucleic acid testing (NAT) and pathogen reduction technologies (PRTs) have markedly increased the safety of blood transfusions by reducing the risk of transfusion-transmitted infections (TTIs), which is crucial for HIV-infected individuals with AA. In addition to safety improvements, tailored transfusion protocols have become increasingly important. The use of leukoreduced blood products helps mitigate the risk of alloimmunization and transfusion-related reactions, while strategies to optimize blood utilization, such as the use of hematopoietic growth factors, aim to minimize the frequency of transfusions. These advancements are designed to address the specific needs of AA patients with HIV, ensuring more effective and personalized care.

Keywords: *Aplastic anemia, HIV, transfusion medicine, blood transfusion, hematology*

Introduction

Aplastic anemia (AA) is a severe hematologic disorder characterized by the failure of the bone marrow to produce adequate amounts of blood cells, resulting in pancytopenia. This condition leads to a range of complications, including anemia, neutropenia, and thrombocytopenia, which can significantly impact patient health and quality of life. In HIV-infected individuals, the management of AA is further complicated by the underlying immunocompromised state induced by the virus. This combination of bone marrow failure and a weakened immune system presents unique challenges in treatment and management. The incidence of AA in HIV-infected patients is

Citation: Obeagu EI. Aplastic Anemia in HIV: Updates in Transfusion Medicine Practices. *Elite Journal of Haematology, 2024; 2(9):* 46-57

influenced by several factors, including the direct effects of HIV on hematopoietic cells and the secondary effects of opportunistic infections and treatments. HIV-related AA can result from the virus's direct cytotoxic effects on hematopoietic stem cells, the development of autoimmune reactions, or the consequences of antiretroviral therapy (ART). These complexities necessitate a multifaceted approach to treatment, with blood transfusions playing a critical role in managing the severe cytopenias associated with AA.[1-5] Recent advancements in transfusion medicine have significantly improved the safety and efficacy of blood transfusions for AA patients, including those with HIV. Enhanced blood screening technologies, such as nucleic acid testing (NAT), and pathogen reduction technologies (PRTs) have substantially reduced the risk of transfusion-transmitted infections (TTIs). These innovations are particularly crucial for HIV-infected patients, who are at heightened risk for infections due to their compromised immune systems. NAT and PRTs help ensure the safety of blood products by detecting and inactivating potential pathogens, thereby minimizing the risk of transfusion-related complications. In addition to improvements in blood safety, recent updates in transfusion protocols have focused on minimizing the risks associated with frequent transfusions. The use of leukoreduced blood products, which have had their white blood cells removed, helps reduce the incidence of alloimmunization and transfusion-related reactions. For AA patients with HIV, this approach is especially beneficial as it can decrease the likelihood of developing antibodies against transfused blood components, which can complicate future transfusions and treatment.[6-10]

Optimizing blood utilization is another area of focus in the management of AA in HIV-infected patients. Advances in hematopoietic growth factors, such as erythropoiesis-stimulating agents (ESAs) and granulocyte colony-stimulating factors (G-CSFs), provide additional strategies to reduce the need for transfusions. These growth factors can stimulate the production of red blood cells and white blood cells, thereby decreasing the frequency of transfusions and improving overall patient outcomes. Infection control remains a critical concern in transfusion medicine for HIV-infected individuals. Rigorous infection prevention measures, including stringent donor screening and hospital infection control protocols, are essential to minimize the risk of infections associated with transfusions. Prophylactic treatments, such as antibiotics and anti-fungal agents, may also be employed to prevent infections in patients who receive frequent transfusions.[11-15]

Blood Screening and Testing

Blood screening and testing have undergone significant advancements in recent years, profoundly impacting the safety and efficacy of transfusions for patients with aplastic anemia (AA), particularly those infected with HIV. For these patients, rigorous screening and testing protocols are crucial to minimize the risk of transfusion-transmitted infections (TTIs) and ensure the highest standards of blood safety. Nucleic acid testing (NAT) represents a major advancement in blood screening technology. NAT detects the presence of viral RNA or DNA in blood products, providing a higher level of sensitivity compared to traditional serological tests. This method allows for the early detection of infectious agents such as HIV, hepatitis B (HBV), and hepatitis C (HCV), which is particularly critical for HIV-infected patients who are already at increased risk for infections. By identifying these pathogens at very low levels, NAT significantly reduces the risk of TTIs and improves patient safety.[16-20] Pathogen reduction technologies (PRTs) have been developed to

further enhance blood safety by inactivating pathogens present in blood products. These technologies utilize methods such as ultraviolet (UV) light, chemical treatments, or riboflavin phototherapy to target and eliminate a broad spectrum of pathogens, including viruses, bacteria, and parasites. PRTs provide an additional layer of protection by ensuring that even if a pathogen is present, it is rendered inactive before transfusion. For HIV-infected patients with AA, PRTs help mitigate the risk of acquiring new infections through transfusions, which is essential for maintaining their health. Traditional serological screening methods have also seen improvements in sensitivity and specificity. Enhanced serological assays can more accurately detect antibodies and antigens related to TTIs, contributing to a more comprehensive screening process. For AA patients with HIV, these advancements help ensure that blood products are free from harmful infectious agents, reducing the likelihood of adverse transfusion reactions.[21-25]

Rigorous donor screening is a fundamental component of blood safety. Donors undergo thorough health evaluations and are assessed for risk factors associated with infectious diseases. In the context of HIV, special attention is given to potential donors' history and current health status to prevent the donation of contaminated blood. Advanced screening protocols, including detailed questionnaires and additional testing, help identify and exclude high-risk donors, further reducing the risk of TTIs. Once blood is collected, it undergoes comprehensive testing and quality control processes to ensure its safety. Blood products are tested for various parameters, including compatibility with recipient blood types and the absence of pathogens. This rigorous testing process helps prevent transfusion reactions and ensures that blood products meet safety standards. For AA patients with HIV, maintaining high-quality control standards is crucial for avoiding complications associated with transfusions.[26-30] Research and development in blood screening technologies continue to evolve, with emerging innovations aimed at enhancing blood safety further. Novel methods, such as next-generation sequencing and advanced multiplex assays, are being explored to improve the detection of rare pathogens and genetic variations that may impact transfusion safety. These emerging technologies hold promise for further reducing the risks associated with blood transfusions. Personalized approaches to blood screening are becoming more feasible with advancements in genomics and molecular diagnostics. Tailoring blood screening protocols based on individual patient needs and risk profiles can optimize transfusion safety. For HIV-infected patients with AA, personalized screening strategies may address specific concerns related to their immunocompromised state and treatment history.[31-35]

Transfusion Protocols and Strategies

The management of aplastic anemia (AA) in HIV-infected patients necessitates the development and implementation of specialized transfusion protocols and strategies to address the complexities of both conditions. These protocols aim to optimize the use of blood products, minimize associated risks, and enhance patient outcomes. Recent advancements in transfusion practices have introduced several key strategies that are particularly relevant for this patient population. One of the most significant advancements in transfusion medicine is the use of leukoreduced blood products. Leukoreduction involves the removal of white blood cells from blood components, which helps reduce the risk of alloimmunization and febrile non-hemolytic transfusion reactions. For HIV-infected patients with AA, who may require frequent transfusions, leukoreduced products

are particularly important as they lower the likelihood of developing antibodies against transfused blood components, which can complicate future transfusions and treatment.[36-40] The use of hematopoietic growth factors, such as erythropoiesis-stimulating agents (ESAs) and granulocyte colony-stimulating factors (G-CSFs), has become an integral part of managing AA. These agents stimulate the production of red blood cells and white blood cells, respectively, and can reduce the need for frequent blood transfusions. For HIV-infected patients, who are often at greater risk for infections and complications, the judicious use of growth factors can help minimize the volume of transfusions required, thereby reducing the associated risks. Establishing appropriate transfusion thresholds is crucial for optimizing transfusion therapy in AA patients. Evidence-based guidelines suggest that transfusions should be administered based on clinical indications and individualized patient needs, rather than strict hemoglobin or platelet count thresholds. For HIV-infected patients, who may have fluctuating blood counts due to both AA and HIV-related factors, personalized transfusion thresholds help ensure that transfusions are given only when necessary and that they are tailored to each patient's specific clinical condition.[41-45]

Effective blood utilization management is essential for minimizing the frequency of transfusions and ensuring the optimal use of available blood products. Strategies such as using smaller transfusion volumes, implementing restrictive transfusion protocols, and employing alternatives like intravenous iron therapy or erythropoiesis-stimulating agents can help manage blood supply more efficiently. For HIV-infected patients with AA, these strategies are particularly valuable in reducing the overall burden of transfusions and associated risks. Pre-transfusion compatibility testing, including blood typing and crossmatching, is a critical step in preventing transfusion reactions and ensuring the safety of transfusions. Advanced compatibility testing methods, such as extended blood typing and antigen-negative blood selection, help match blood products more precisely to the recipient's needs. For AA patients with HIV, these practices are crucial in avoiding alloimmunization and ensuring that transfused blood products are well-tolerated.[46-50] Alloimmunization, or the development of antibodies against transfused blood components, is a significant concern for patients undergoing frequent transfusions. Strategies to manage alloimmunization include regular antibody screening, the use of antigen-negative blood products, and employing specialized blood bank services for patients with a history of alloimmunization. For HIV-infected patients with AA, addressing alloimmunization effectively is essential for maintaining a compatible and safe transfusion therapy. Infection prevention measures are a critical component of transfusion protocols, especially for HIV-infected patients who are at higher risk for infections. Rigorous infection control practices, including sterile techniques during transfusion, and prophylactic treatments such as antibiotics or antifungal agents, help minimize the risk of transfusion-related infections. Ensuring that these measures are followed diligently contributes to the overall safety of transfusion therapy.[51-55] A patient-centered approach to transfusion therapy involves considering the individual needs and preferences of AA patients with HIV. This approach includes engaging patients in decision-making, providing education about transfusion options, and addressing their concerns about treatment. Personalized care plans that take into account the patient's overall health, HIV status, and specific transfusion needs help improve adherence to treatment and enhance patient outcomes.[56-57]

Infection Control and Management

Infection control and management are critical components of care for patients with aplastic anemia (AA) who are also HIV-infected. These patients are particularly vulnerable to infections due to their compromised immune systems and the frequent use of blood transfusions, which can introduce potential pathogens. Implementing robust infection control measures is essential for minimizing infection risks and ensuring optimal patient outcomes. Rigorous donor screening processes are fundamental in preventing transfusion-transmitted infections (TTIs). Potential blood donors undergo comprehensive health assessments, including detailed questionnaires about their medical history and risk factors for infectious diseases. For HIV-infected patients with AA, ensuring that blood products are sourced from thoroughly screened and tested donors reduces the risk of introducing infectious agents through transfusions. Enhanced screening protocols help identify and exclude high-risk donors, thereby maintaining the safety of the blood supply.[58-62] Nucleic acid testing (NAT) has become a cornerstone of infection control in blood transfusion practices. NAT allows for the early detection of viral RNA or DNA, including HIV, hepatitis B (HBV), and hepatitis C (HCV), which may be present in very low concentrations in donated blood. For patients with HIV and AA, NAT provides a higher level of safety by identifying and eliminating blood products that could transmit infections. This technology is especially crucial for this patient group, given their heightened susceptibility to infections. Pathogen reduction technologies (PRTs) further enhance the safety of blood transfusions by inactivating a broad spectrum of pathogens. Methods such as ultraviolet (UV) light treatment, chemical inactivation, and riboflavin phototherapy are used to target and destroy viruses, bacteria, and parasites in blood products. PRTs add an additional layer of protection, reducing the likelihood of TTIs and infections in HIV-infected patients with AA. The application of PRTs ensures that even if a pathogen is present, it is effectively neutralized before transfusion.[63-67]

Prophylactic measures play a crucial role in infection control for HIV-infected AA patients. This includes the use of antibiotics, antivirals, and antifungal agents to prevent opportunistic infections that are common in immunocompromised individuals. Regular surveillance and monitoring for signs of infections allow for early detection and prompt treatment, minimizing the impact of infections on patient health. Prophylactic strategies are tailored based on individual patient needs and risk factors, providing a personalized approach to infection management. Maintaining strict sterile techniques during the transfusion process is essential for preventing the introduction of pathogens. This includes the use of sterile equipment, adherence to proper hand hygiene, and following protocols for the preparation and administration of blood products. For HIV-infected patients with AA, adhering to these practices reduces the risk of transfusion-related infections and ensures a safer transfusion experience.[68-72] Infection control extends beyond the transfusion process to encompass broader healthcare settings. Rigorous infection control practices within hospitals and clinics, including environmental cleaning, isolation precautions, and staff training, are crucial for reducing the risk of healthcare-associated infections. For HIV-infected patients with AA, these practices help protect against nosocomial infections and ensure a safer overall healthcare environment. Educating patients about infection prevention and control measures is a key aspect of infection management. Providing information on recognizing symptoms of infections, proper hygiene practices, and the importance of adherence to prophylactic treatments empowers patients to take an active role in their care. Engaged patients are better equipped to manage their health and reduce their risk of infections. Collaboration with infectious disease specialists is valuable for

managing complex cases involving HIV-infected patients with AA. These specialists provide expertise in navigating the intricacies of infection prevention, diagnosis, and treatment. Their input is crucial in developing and implementing effective infection control strategies tailored to the needs of this patient population.[73-77]

Alloimmunization and Blood Compatibility

Alloimmunization and blood compatibility are critical concerns in the management of patients with aplastic anemia (AA), especially those who are also HIV-infected. These issues impact the safety and efficacy of blood transfusions, which are a key component of treatment for AA. Alloimmunization occurs when a patient develops antibodies against antigens on transfused blood cells that are not present in their own blood. This immune response can lead to the formation of antibodies against foreign blood group antigens, which can complicate future transfusions. In patients with AA, frequent transfusions increase the likelihood of alloimmunization, making it a significant concern. HIV-infected individuals may be at higher risk due to their compromised immune systems and potential for repeated transfusions. Blood compatibility is determined by the presence or absence of specific blood group antigens on red blood cells. The most commonly tested blood group systems include ABO and Rh, but other less common antigens (e.g., Kell, Duffy, Kidd) can also be relevant. Alloimmunization occurs when the recipient's immune system recognizes these foreign antigens and mounts an immune response. For AA patients with HIV, ensuring compatibility across multiple blood group systems is crucial to avoid alloimmunization and transfusion reactions.[79-82]

One effective strategy to reduce the risk of alloimmunization is the use of leukoreduced blood products. Leukoreduction removes most white blood cells from the blood components, which decreases the likelihood of developing antibodies against transfused blood. This is particularly important for HIV-infected AA patients who may require frequent transfusions, as leukoreduction helps minimize alloimmunization and reduces the risk of transfusion-related reactions. Regular antibody screening and identification are essential for managing alloimmunization. Prior to transfusion, patients are tested for the presence of existing antibodies against blood group antigens. If antibodies are detected, blood bank personnel perform crossmatching to ensure compatibility between the donor and recipient blood. For AA patients with HIV, comprehensive antibody screening helps prevent transfusion reactions and ensures that compatible blood products are used. For patients who have developed antibodies against specific blood group antigens, antigen-negative blood products are used to avoid alloimmunization. Blood banks can identify and provide blood products that lack the specific antigens against which the patient has antibodies. This approach is crucial for managing patients with a history of alloimmunization, including those with AA and HIV, to ensure that transfusions are safe and effective.[83-85]

Implementing individualized transfusion protocols can further enhance blood compatibility and minimize the risk of alloimmunization. These protocols involve tailoring transfusion practices based on the patient's blood type, antibody profile, and transfusion history. For HIV-infected patients with AA, personalized transfusion strategies are essential for addressing the unique challenges posed by their condition and ensuring the best possible outcomes. Alloimmunization can complicate future transfusions by making it more difficult to find compatible blood products.

This can lead to delays in treatment and increased risk of transfusion reactions. For AA patients with HIV, managing alloimmunization effectively is crucial to ensure that they have access to safe and compatible blood products when needed. Advances in blood compatibility testing technologies, such as molecular genotyping and high-resolution antigen typing, have improved the accuracy of compatibility assessments. These technologies provide more detailed information about blood group antigens, allowing for better matching of blood products and reducing the risk of alloimmunization. For HIV-infected AA patients, these advancements enhance the precision of transfusion therapy and improve overall patient safety.[86-87]

Conclusion

In the management of aplastic anemia (AA) in HIV-infected patients, ensuring the safety and effectiveness of blood transfusions is of paramount importance. The integration of advanced transfusion practices, such as leukoreduction, pathogen reduction technologies, and individualized transfusion protocols, is essential for optimizing patient outcomes. Enhanced infection control measures, including rigorous donor screening, nucleic acid testing, and pathogen reduction, play a crucial role in safeguarding against transfusion-transmitted infections. These practices are vital in protecting HIV-infected patients, who are particularly vulnerable to infections due to their compromised immune systems. Additionally, implementing effective infection prophylaxis and maintaining stringent sterile techniques further contribute to reducing infection risks.

References

1. Furlong E, Carter T. Aplastic anaemia: Current concepts in diagnosis and management. Journal of paediatrics and child health. 2020;56(7):1023-1028.
2. Chichetto NE, Polanka BM, So-Armah KA, Sung M, Stewart JC, Koethe JR, Edelman EJ, Tindle HA, Freiberg MS. Contribution of behavioral health factors to non-AIDS-related comorbidities: an updated review. Current HIV/AIDS Reports. 2020; 17:354-372.
3. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV, 2024; 2(1): 65-78
4. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
5. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 46-58
6. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(1):21-31
7. Obeagu EI, GU Obeagu. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health, 2024; 2 (1): 8-22
8. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com. 2024;12(01).
9. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine, 2024;2(1): 35-46

Citation: Obeagu EI. Aplastic Anemia in HIV: Updates in Transfusion Medicine Practices. *Elite Journal of Haematology, 2024; 2(9):* 46-57

10. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology, 2024; 2(1): 34-46
11. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15
12. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science, 2024; 2(1): 33-42
13. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64
14. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology, 2024; 2(1): 1-13
15. Felker-Kantor EA, Wallace ME, Madkour AS, Duncan DT, Andrinopoulos K, Theall K. HIV stigma, mental health, and alcohol use disorders among people living with HIV/AIDS in New Orleans. Journal of urban health. 2019; 96:878-888.
16. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Asian J Dental Health Sci 2024;4(1):38-44. Available from: http://ajdhs.com/index.php/journal/article/view/63
17. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV, 2024; 2(2): 1-17
18. Obeagu EI, Obeagu GU.Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health, 2024; 2 (1): 22-34
19. Skalski LM, Sikkema KJ, Heckman TG, Meade CS. Coping styles and illicit drug use in older adults with HIV/AIDS. Psychology of Addictive Behaviors. 2013;27(4):1050.
20. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine, 2024; 2(2):104-115
21. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS spread: impact of religious leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
22. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
23. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.
24. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
25. Hill K, Kuo I, Shenoi SV, Desruisseaux MS, Springer SA. Integrated care models: HIV and substance use. Current HIV/AIDS Reports. 2023;20(5):286-295.

26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
27. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
28. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci [Internet]. 2023 Jun. 15 [cited 2024 Sep. 7];3(2):7-14. Available from: http://ajdhs.com/index.php/journal/article/view/39
29. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
30. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
31. Alum EU, Obeagu EI, Ugwu OP, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine. 2023 Oct 13;102(41):e35673.
32. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
33. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
34. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
35. Goodwin M. Black markets: the supply and demand of body parts. Cambridge University Press; 2006.
36. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
37. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
38. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
39. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
40. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda . Elite Journal of Medicine, 2024; 2(1): 1-16
41. Mandania EW. Haematological and Immunological Abnormalities in People Living With HIV: A Review. Journal of Medical and Biomedical Laboratory Sciences Research. 2024;4(1).

Citation: Obeagu EI. Aplastic Anemia in HIV: Updates in Transfusion Medicine Practices. *Elite Journal of Haematology, 2024; 2(9):* 46-57

42. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
43. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
44. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26
45. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
46. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73
47. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
48. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Applied Sciences (NIJBAS). 2023;3(3).
49. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
50. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
51. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
52. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
53. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20-35
54. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
55. American Psychiatric Association. Practice guideline for the treatment of patients with HIV/AIDS. American Psychiatric Pub; 2000.
56. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
57. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72

Citation: Obeagu EI. Aplastic Anemia in HIV: Updates in Transfusion Medicine Practices. *Elite Journal of Haematology, 2024; 2(9):* 46-57

58. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
59. Sukumaran RK. Long-Term Follow-Up and Chronic Complications. Contemporary Bone Marrow Transplantation. 2021:641-665.
60. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
61. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
62. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
63. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
64. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
65. Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M. Stigma, disclosure, coping, and medication adherence among people living with HIV/AIDS in Northern Tanzania. AIDS patient care and STDs. 2014;28(2):98-105.
66. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
67. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
68. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
69. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
70. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
71. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
72. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
73. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
74. Banerjee N, Goodman ZT, McIntosh R, Ironson G. Cognition, coping, and psychological distress in HIV. AIDS and Behavior. 2022;26(4):1074-1083.
75. Grau LE, Griffiths-Kundishora A, Heimer R, Hutcheson M, Nunn A, Towey C, Stopka TJ. Barriers and facilitators of the HIV care continuum in Southern New England for people

with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers. Addiction science & clinical practice. 2017; 12:1-4.

76. Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. BMC public health. 2018; 18:1-8.
77. Li H, Wu X, Shen J, Lou S. Perspective and experience of patients with aplastic anemia on medication adherence. Patient preference and adherence. 2023:2215-2225.
78. Beichler H, Grabovac I, Dorner TE. Integrated care as a model for interprofessional disease management and the benefits for people living with HIV/AIDS. International Journal of Environmental Research and Public Health. 2023;20(4):3374.
79. Rajabiun S, Tryon J, Feaster M, Pan A, McKeithan L, Fortu K, Cabral HJ, Borne D, Altice FL. The influence of housing status on the HIV continuum of care: results from a multisite study of patient navigation models to build a medical home for people living with HIV experiencing homelessness. American Journal of Public Health. 2018;108(S7):S539-45.
80. Dale SK, Safren SA. Striving towards empowerment and medication adherence (STEP-AD): a tailored cognitive behavioral treatment approach for black women living with HIV. Cognitive and Behavioral Practice. 2018;25(3):361-376.
81. Ngcobo S, Scheepers S, Mbatha N, Grobler E, Rossouw T. Roles, barriers, and recommendations for community health workers providing community-based HIV Care in Sub-Saharan Africa: a review. AIDS Patient Care and STDs. 2022;36(4):130-144.
82. Obeagu EI, Ogu RIO, Ngwoke AO. Psychosocial Impact of Aplastic Anemia Diagnosis in HIV Patients: A Narrative Review. Elite Journal of Public Health, 2024; 2 (7): 35-46
83. Obeagu EI, Akinleye CA. Stabilizing Hemoglobin Levels: A Vital Aspect of Blood Transfusions in HIV Management. *Elite Journal of Haematology, 2024; 2(9):* 1-8
84. Obeagu EI, Akinleye CA. Promoting Fertility: Blood Transfusions and Reproductive Health in HIV-Positive Individuals. *Elite Journal of Haematology, 2024; 2(9):* 9-16
85. Obeagu EI, Akinleye CA. Minimizing Treatment-Related Depression: Blood Transfusions and Mental Health Support in HIV Care. Elite Journal of Public Health, 2024; 2 (7): 16-24
86. Obeagu EI, Akinleye CA. Promoting Social Integration: Blood Transfusions and Improved Social Well-being in HIV Patients. Elite Journal of Public Health, 2024; 2 (7): 25-34
87. Obeagu EI, Akinleye CA. Optimizing Physical Endurance: Blood Transfusions in HIV and the Improvement of Exercise Capacity. Elite Journal of Medicine, 2024; 2(9): 1-9